SCHEMBL12207641

SCHEMBL12207641

c1ccc(N(c2ccccc2)c2ccc(-c3ccc(N(c4ccccc4)c4ccc(-c5nc6ccccc6nc5-c5ccc(N(c6ccccc6)c6ccc(-c7ccc(N(c8ccccc8)c8ccccc8)cc7)cc6)cc5)cc4)cc3)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 7/20 0.55
KDM4E B2RXH2 6/20 0.55
LMNA P02545 4/20 0.55
TDP1 Q9NUW8 3/20 0.55
KMT2A Q03164 2/20 0.55
GAA P10253 2/20 0.55
MEN1 O00255 1/20 0.55
ALDH1A1 P00352 5/20 0.50
NPSR1 Q6W5P4 1/20 0.50
AKT1 P31749 1/20 0.47
AKT2 P31751 1/20 0.47
PKM P14618 1/20 0.47
MAPK10 P53779 1/20 0.46
MAPK14 Q16539 1/20 0.46
THRB P10828 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12690838 1.00 L3MBTL1 (0.55) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL12207672 1.00 L3MBTL1 (0.55) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL4758408 1.00 L3MBTL1 (0.55) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL4750680 0.98 KDM4E (0.58) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL12690611 0.98 KDM4E (0.58) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL12146744 0.98 KDM4E (0.58) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL12146594 0.98 KDM4E (0.58) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL12207627 0.98 KDM4E (0.58) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL12207633 0.98 KDM4E (0.58) L3MBTL1KDM4ELMNATDP1KMT2A
SCHEMBL12146745 0.98 KDM4E (0.58) L3MBTL1KDM4ELMNATDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004616-B1 QUINOXALINE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE USING THE QUINOXALINE DERIVATIVE SEMICONDUCTOR ENERGY LAB (JP) 2014-05-21 EP disclosed
US-8471017-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO. LTD. (JP) 2013-06-25 US disclosed
US-8471017-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO. LTD. (JP) 2013-06-25 US disclosed
US-20110248254-A1 QUINOXALINE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE USING THE QUINOXALINE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-10-13 US disclosed
US-20110248254-A1 QUINOXALINE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE USING THE QUINOXALINE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2011-10-13 US disclosed
US-7696348-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORIES CO., LTD. (JP) 2010-04-13 US disclosed
WO-2007108403-A1 QUINOXALINE DERIVATIVE, AND LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE USING THE QUINOXALINE DERIVATIVE SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2007-09-27 WO disclosed
US-20070222374-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070222374-A1 Quinoxaline derivative, and light-emitting element, light-emitting device, electronic device using the quinoxaline derivative NDUFA9, MT-ND1, NQO2 L3MBTL1 1414/4885KDM4E 2330/4885LMNA 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.